Trials / Completed
CompletedNCT03634969
An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of BMS-986224 in Participants With Varying Degrees of Renal Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the experimental medication BMS-986224 in participants with varying levels of renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986224 | Specified dose on specified days |
Timeline
- Start date
- 2018-08-14
- Primary completion
- 2019-04-30
- Completion
- 2019-04-30
- First posted
- 2018-08-17
- Last updated
- 2020-02-25
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03634969. Inclusion in this directory is not an endorsement.